SART3: A Protein Target for Drug Development (G9733)

Target Name: SART3

NCBI ID: G9733

SART3

SART3: A Protein Target for Drug Development

SART3, also known as Spliceosome Associated Factor 3, is a protein that is expressed in various tissues throughout the body. It plays a critical role in the regulation of gene expression, specifically in the process of splicing RNA into functional mature proteins. SART3 is also involved in the recycling of a protein called U4/U6, which is a key regulator of spliceosome maturation.

Recent studies have identified SART3 as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The focus of these studies is to identify small molecules that can interact with SART3 and inhibit its activity, potentially leading to the development of new treatments.

One approach that has been used to identify potential drug targets for SART3 is high-throughput screening (HTS) assays. These assays involve screening a large library of small molecules against a protein to identify those that interact with the protein and are able to inhibit its activity. One of the main advantages of HTS assays is their ability to identify compounds that are specific for a protein, as well as their ability to quickly and efficiently identify potential drug targets.

Another approach that has been used to identify potential drug targets for SART3 is mass spectrometry (MS). MS is a technique that involves identifying the mass of a protein using its amino acid sequence. By comparing the mass of a protein to its expected mass, researchers can identify potential mutations or alterations in the protein that may be involved in its function. MS can also be used to identify potential drug targets by identifying small molecules that interact with the protein and are able to alter its activity.

In addition to these approaches, researchers have also used computational tools to predict the potential drug targets for SART3. These tools use advanced algorithms to predict the binding of small molecules to the protein and identify potential drug targets that are likely to be effective.

Overall, the identification of SART3 as a potential drug target for a variety of diseases has significant implications for the development of new treatments. Further research is needed to fully understand the function of SART3 and to identify small molecules that can interact with it.

Protein Name: Spliceosome Associated Factor 3, U4/U6 Recycling Protein

Functions: U6 snRNP-binding protein that functions as a recycling factor of the splicing machinery. Promotes the initial reassembly of U4 and U6 snRNPs following their ejection from the spliceosome during its maturation (PubMed:12032085). Also binds U6atac snRNPs and may function as a recycling factor for U4atac/U6atac spliceosomal snRNP, an initial step in the assembly of U12-type spliceosomal complex. The U12-type spliceosomal complex plays a role in the splicing of introns with non-canonical splice sites (PubMed:14749385). May also function as a substrate-targeting factor for deubiquitinases like USP4 and USP15. Recruits USP4 to ubiquitinated PRPF3 within the U4/U5/U6 tri-snRNP complex, promoting PRPF3 deubiquitination and thereby regulating the spliceosome U4/U5/U6 tri-snRNP spliceosomal complex disassembly (PubMed:20595234). May also recruit the deubiquitinase USP15 to histone H2B and mediate histone deubiquitination, thereby regulating gene expression and/or DNA repair (PubMed:24526689). May play a role in hematopoiesis probably through transcription regulation of specific genes including MYC (By similarity)

The "SART3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SART3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets